Both the studies showed that the investigational drug candidate was statistically superior to placebo for all primary and secondary endpoints.
Efinaconazole was also found to be generally safe and well tolerated.
Efinaconazole is an investigational antifungal drug belonging to the triazole family, which has not been found by the US FDA to be safe or effective for the treatment of mild to moderate onychomycosis of the toenail.
Valeant holds an exclusive license from Kaken Pharmaceutical to commercialize efinaconazole in North America, Central America, South America and the European Union.